Efficacy of Mirabegron, Solifenacin, Tamsulosine, Tadalafil and Their Combinations in the Treatment of Double-J Stent-Related Lower Urinary Tract Symptoms

Muhammad Asykar Palinrungi0 个研究点目标入组 161 人开始时间: 2022年10月14日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion criterias are willing to undergo voluntary research, age 18 to 79 years old, has indications of endoscopic ureteral stent insertion, is diagnosed with ureteral stones less than 10 mm (with or without dilatation of pelvic, calix, ureter), ureteral stenosis, and or kidney stones and will undergo shockwave lithotripsy (ESWL), has had the first insertion of ureteral stent, and has indications for the unilateral ureteral stent insertion.

•Exclusion criterias are history of malignancy in the urinary tract, history of hypertrophic prostate, history of previous sexual dysfunction, having had a urinary tract infections in the previous 6 months, pregnancy, history of diabetes mellitus, cardiovascular disease, or hypertension, having or undergoing radiation therapy, hormonal therapy, and or minor pelvic surgical procedures, previous surgery of ureteral reconstruction, history of alcoholism, history of stroke, having Alzheimers disease, having central nervous system trauma, having accompanying stones in the bladder, history of urethra diverticula in women, and hypersensitivity to Tadalafil or Tamsulosin or Mirabegron or Solifenacin.

发起方

Muhammad Asykar Palinrungi